Loading
An enzyme blocker meant to stop tumours starving T cells of tryptophan. Its 2018 phase 3 failure ended an entire class overnight.
IDO1 degrades tryptophan to kynurenine, suppressing T cells. Epacadostat plus pembrolizumab produced ~55% response rates in a phase 1/2 melanoma cohort. ECHO-301/KEYNOTE-252 (n=706, first-line melanoma) showed no PFS or OS difference (2018). Incyte, Merck, BMS, and others halted more than a dozen IDO1 trials within weeks; the drug may never have achieved adequate pathway inhibition in tumours.
Lesson: pharmacodynamic proof of target engagement in the tumour should precede phase 3; a large uncontrolled response rate on a pembrolizumab backbone in melanoma is not evidence of added benefit.
Selective, reversible IDO1 enzyme inhibitor. Connects to IDO1.
1.Epacadostat slips into a pocket on IDO1.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Epacadostat" OR ABSTRACT:"Epacadostat" OR TITLE:"INCB024360" OR ABSTRACT:"INCB024360") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Epacadostat, not a curated reading list.
Shares No accelerated approval for a combination without proof each part contributes, Pembrolizumab, Immune checkpoint inhibitors and the tag failure.
Shares No accelerated approval for a combination without proof each part contributes, Cold tumours and the immunosuppressive microenvironment, Failures are hidden, Immune checkpoint inhibitors and the tag failure.
Shares Public post-mortem reports when a cancer drug programme is stopped, Failures are hidden and the tag failure.
Shares Public post-mortem reports when a cancer drug programme is stopped, Cold tumours and the immunosuppressive microenvironment, Failures are hidden and the tag failure.
Shares Melanoma, Pembrolizumab, Immune checkpoint inhibitors and the tag failure.
Shares Cold tumours and the immunosuppressive microenvironment, Melanoma and the tag failure.
Shares Failures are hidden, Melanoma and the tag failure.
Shares Melanoma, Immune checkpoint inhibitors and the tag failure.